Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03376321




Registration number
NCT03376321
Ethics application status
Date submitted
12/12/2017
Date registered
18/12/2017
Date last updated
14/04/2021

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
Scientific title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection
Secondary ID [1] 0 0
2017-002156-84
Secondary ID [2] 0 0
CR108399
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza A 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Pimodivir 600 mg
Treatment: Drugs - Placebo
Other interventions - SOC Treatment

Experimental: Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment) - Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).

Placebo comparator: Treatment Arm 2 (placebo + SOC treatment) - Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.


Treatment: Drugs: Pimodivir 600 mg
Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).

Treatment: Drugs: Placebo
Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).

Other interventions: SOC Treatment
Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Hospital Recovery Scale on Day 6
Timepoint [1] 0 0
Day 6
Secondary outcome [1] 0 0
Time to Hospital Discharge
Timepoint [1] 0 0
Up to Day 33
Secondary outcome [2] 0 0
Number of Participants With Adjudicated Influenza Complications
Timepoint [2] 0 0
Up to Day 33
Secondary outcome [3] 0 0
Viral Load Over Time
Timepoint [3] 0 0
Baseline, Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 14 and 19
Secondary outcome [4] 0 0
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Timepoint [4] 0 0
Up to Day 33
Secondary outcome [5] 0 0
Number of Participants With Emergence of Viral Resistance to Pimodivir
Timepoint [5] 0 0
Up to Day 33
Secondary outcome [6] 0 0
Plasma Concentration of Pimodivir
Timepoint [6] 0 0
Day 1: 1 hour30minutes to 6 hours postdose, Day 3: Predose, Day 5: Predose and 1 hour30minutes to 6 hours postdose, Day 6: 12 hours postdose
Secondary outcome [7] 0 0
Number of Participants With Clinically Significant Changes in Laboratory Tests
Timepoint [7] 0 0
Up to Day 33
Secondary outcome [8] 0 0
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
Timepoint [8] 0 0
Up to Day 33
Secondary outcome [9] 0 0
Number of Participants With Clinically Significant Changes in Vital Signs
Timepoint [9] 0 0
Up to Day 33

Eligibility
Key inclusion criteria
* Tested positive for influenza A infection after the onset of symptoms using a polymerase chain reaction (PCR)-based or other rapid molecular diagnostic assay
* Requires hospitalization to treat influenza infection and/or to treat complications of influenza infection (for example, radiological signs of lower respiratory tract disease, septic shock, central nervous system [CNS] involvement, myositis, rhabdomyolysis, acute exacerbation of chronic kidney disease, severe dehydration, myocarditis, pericarditis, ischemic heart disease, exacerbation of underlying chronic pulmonary disease, including asthma, chronic obstructive pulmonary disease [COPD], decompensation of previously controlled diabetes mellitus), including participants admitted to the Intensive Care Unit (ICU)
* Enrollment and initiation of study drug treatment less than or equal to (<=)96 hours after onset of influenza symptoms
* Being on invasive mechanical ventilation or having a peripheral capillary oxygen saturation (SpO2) less than (<)94 percent (%) on room air during screening. Participants with known pre-influenza SpO2 <94% must have an SpO2 decline greater than or equal to (>=)3% from pre-influenza SpO2 during screening
* Having a screening/baseline National Early Warning Score 2 (NEWS2) of >=4
Minimum age
13 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Received more than 3 doses of influenza antiviral medication (for example, oseltamivir [OST] or zanamivir), or any dose of ribavarin (RBV) within 2 weeks, prior to first study drug intake. Received intravenous (IV) peramivir more than one day prior to screening
* Unstable angina pectoris or myocardial infarction within 30 days prior to screening (inclusive)
* Presence of clinically significant heart arrhythmias, uncontrolled, unstable atrial arrhythmia, or sustained ventricular arrhythmia, or risk factors for Torsade de Pointes syndrome
* Known severe hepatic impairment (Child Pugh C cirrhosis) or chronic hepatitis C infection undergoing hepatitis C antiviral therapy
* Severely immunocompromised in the opinion of the investigator (for example, known cluster of differentiation 4 plus [CD4+] count <200 cells per cubic millimeter [cells/mm^3], absolute neutrophil count <750/mm^3, first course of chemotherapy completed within 2 weeks prior to screening, history of stem cell transplant within 1 year prior to screening, any history of a lung transplant)
* Known allergies, hypersensitivity, or intolerance to pimodivir or its excipients

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/01/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/04/2020
Sample size
Target
Accrual to date
Final
334
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [3] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment hospital [5] 0 0
Mater Hospital Brisbane - South Brisbane
Recruitment hospital [6] 0 0
Townsville Hospital - Townsville
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
3050 - Melbourne
Recruitment postcode(s) [5] 0 0
4101 - South Brisbane
Recruitment postcode(s) [6] 0 0
4814 - Townsville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Montana
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
Argentina
State/province [18] 0 0
Bahia Blanca
Country [19] 0 0
Argentina
State/province [19] 0 0
C.a.b.a.
Country [20] 0 0
Argentina
State/province [20] 0 0
Cordoba
Country [21] 0 0
Argentina
State/province [21] 0 0
Córdoba
Country [22] 0 0
Argentina
State/province [22] 0 0
General Roca
Country [23] 0 0
Argentina
State/province [23] 0 0
La Plata Lpl Lpl
Country [24] 0 0
Argentina
State/province [24] 0 0
La Plata
Country [25] 0 0
Argentina
State/province [25] 0 0
Pilar
Country [26] 0 0
Argentina
State/province [26] 0 0
Rosario
Country [27] 0 0
Austria
State/province [27] 0 0
Wien
Country [28] 0 0
Belgium
State/province [28] 0 0
Brussel
Country [29] 0 0
Belgium
State/province [29] 0 0
Bruxelles
Country [30] 0 0
Brazil
State/province [30] 0 0
Belo Horizonte
Country [31] 0 0
Brazil
State/province [31] 0 0
Brasil
Country [32] 0 0
Brazil
State/province [32] 0 0
Passo Fundo
Country [33] 0 0
Brazil
State/province [33] 0 0
Porto Alegre
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Paulo
Country [35] 0 0
Brazil
State/province [35] 0 0
São José do Rio Preto
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Ruse
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Sofia
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Veliko Tarnovo
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Canada
State/province [41] 0 0
Vancouver
Country [42] 0 0
Chile
State/province [42] 0 0
Puente Alto
Country [43] 0 0
Chile
State/province [43] 0 0
San Bernardo
Country [44] 0 0
China
State/province [44] 0 0
Changsha
Country [45] 0 0
China
State/province [45] 0 0
Guangzhou
Country [46] 0 0
China
State/province [46] 0 0
Wuxi
Country [47] 0 0
China
State/province [47] 0 0
Zhengzhou
Country [48] 0 0
Czechia
State/province [48] 0 0
Brno
Country [49] 0 0
Czechia
State/province [49] 0 0
Kyjov
Country [50] 0 0
Czechia
State/province [50] 0 0
Praha 8
Country [51] 0 0
France
State/province [51] 0 0
Agen cedex 9
Country [52] 0 0
France
State/province [52] 0 0
Amiens Cedex
Country [53] 0 0
France
State/province [53] 0 0
Colombes
Country [54] 0 0
France
State/province [54] 0 0
Creteil cedex
Country [55] 0 0
France
State/province [55] 0 0
Dijon
Country [56] 0 0
France
State/province [56] 0 0
La Roche S/ Yon Cedex 9
Country [57] 0 0
France
State/province [57] 0 0
La Tronche
Country [58] 0 0
France
State/province [58] 0 0
Limoges
Country [59] 0 0
France
State/province [59] 0 0
Lyon
Country [60] 0 0
France
State/province [60] 0 0
Marseille cedex 20
Country [61] 0 0
France
State/province [61] 0 0
NANTES Cedex 01
Country [62] 0 0
France
State/province [62] 0 0
Nantes Cedex 1
Country [63] 0 0
France
State/province [63] 0 0
Nice Cedex 3
Country [64] 0 0
France
State/province [64] 0 0
Paris cedex 10
Country [65] 0 0
France
State/province [65] 0 0
Paris
Country [66] 0 0
France
State/province [66] 0 0
Poitiers
Country [67] 0 0
France
State/province [67] 0 0
Saint-Etienne Cedex 2
Country [68] 0 0
Germany
State/province [68] 0 0
Donaustauf
Country [69] 0 0
Germany
State/province [69] 0 0
Erlangen
Country [70] 0 0
Germany
State/province [70] 0 0
Hessen
Country [71] 0 0
Germany
State/province [71] 0 0
Koeln
Country [72] 0 0
Germany
State/province [72] 0 0
Luebeck
Country [73] 0 0
Germany
State/province [73] 0 0
Weiden
Country [74] 0 0
Hungary
State/province [74] 0 0
Farkasgyepü
Country [75] 0 0
Hungary
State/province [75] 0 0
Torokbalint
Country [76] 0 0
India
State/province [76] 0 0
Ahmedabad
Country [77] 0 0
India
State/province [77] 0 0
Balaga
Country [78] 0 0
India
State/province [78] 0 0
Bangalore
Country [79] 0 0
India
State/province [79] 0 0
Gandhinagar
Country [80] 0 0
India
State/province [80] 0 0
Hyderabad
Country [81] 0 0
India
State/province [81] 0 0
Jaipur
Country [82] 0 0
India
State/province [82] 0 0
Lucknow
Country [83] 0 0
India
State/province [83] 0 0
Mangalore
Country [84] 0 0
India
State/province [84] 0 0
Manipal
Country [85] 0 0
India
State/province [85] 0 0
Nagpur
Country [86] 0 0
India
State/province [86] 0 0
Nashik
Country [87] 0 0
India
State/province [87] 0 0
New Delhi
Country [88] 0 0
India
State/province [88] 0 0
Pune
Country [89] 0 0
India
State/province [89] 0 0
Rajkot
Country [90] 0 0
India
State/province [90] 0 0
Surat
Country [91] 0 0
Israel
State/province [91] 0 0
Afula
Country [92] 0 0
Israel
State/province [92] 0 0
Ashkelon
Country [93] 0 0
Israel
State/province [93] 0 0
Beersheba
Country [94] 0 0
Israel
State/province [94] 0 0
Haifa
Country [95] 0 0
Israel
State/province [95] 0 0
Holon
Country [96] 0 0
Israel
State/province [96] 0 0
Jerusalem
Country [97] 0 0
Israel
State/province [97] 0 0
Kfar-Saba
Country [98] 0 0
Israel
State/province [98] 0 0
Nahariya
Country [99] 0 0
Israel
State/province [99] 0 0
Petach Tikva
Country [100] 0 0
Israel
State/province [100] 0 0
Ramat Gan
Country [101] 0 0
Israel
State/province [101] 0 0
Rechovot
Country [102] 0 0
Israel
State/province [102] 0 0
Safed
Country [103] 0 0
Israel
State/province [103] 0 0
Tel Aviv
Country [104] 0 0
Italy
State/province [104] 0 0
Milano
Country [105] 0 0
Italy
State/province [105] 0 0
Modena
Country [106] 0 0
Italy
State/province [106] 0 0
Monza
Country [107] 0 0
Italy
State/province [107] 0 0
Novara
Country [108] 0 0
Italy
State/province [108] 0 0
Palermo
Country [109] 0 0
Italy
State/province [109] 0 0
Roma
Country [110] 0 0
Italy
State/province [110] 0 0
Verona
Country [111] 0 0
Korea, Republic of
State/province [111] 0 0
Ansan-si
Country [112] 0 0
Korea, Republic of
State/province [112] 0 0
Cheongju-si
Country [113] 0 0
Korea, Republic of
State/province [113] 0 0
Gangwon-do
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Hwaseong-si
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Incheon
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Pusan
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Seoul
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Suwon-si
Country [119] 0 0
Latvia
State/province [119] 0 0
Liepaja
Country [120] 0 0
Latvia
State/province [120] 0 0
Rezekne
Country [121] 0 0
Latvia
State/province [121] 0 0
Riga District
Country [122] 0 0
Latvia
State/province [122] 0 0
Riga
Country [123] 0 0
Latvia
State/province [123] 0 0
Valmiera
Country [124] 0 0
Lithuania
State/province [124] 0 0
Klaipeda
Country [125] 0 0
Lithuania
State/province [125] 0 0
Siauliai
Country [126] 0 0
Lithuania
State/province [126] 0 0
Vilnius
Country [127] 0 0
Malaysia
State/province [127] 0 0
Alor Setar
Country [128] 0 0
Malaysia
State/province [128] 0 0
Kota Kinabalu
Country [129] 0 0
Malaysia
State/province [129] 0 0
Kuala
Country [130] 0 0
Malaysia
State/province [130] 0 0
Kuching
Country [131] 0 0
Malaysia
State/province [131] 0 0
Miri
Country [132] 0 0
Malaysia
State/province [132] 0 0
Seremban
Country [133] 0 0
Malaysia
State/province [133] 0 0
Sibu
Country [134] 0 0
Malaysia
State/province [134] 0 0
Sungai Buloh
Country [135] 0 0
Malaysia
State/province [135] 0 0
Taiping
Country [136] 0 0
Mexico
State/province [136] 0 0
Ciudad De Mexico
Country [137] 0 0
Mexico
State/province [137] 0 0
Cuernavaca
Country [138] 0 0
Mexico
State/province [138] 0 0
Guadalajara
Country [139] 0 0
Mexico
State/province [139] 0 0
Mexico
Country [140] 0 0
Netherlands
State/province [140] 0 0
Dordrecht
Country [141] 0 0
Netherlands
State/province [141] 0 0
s-Hertogenbosch
Country [142] 0 0
Netherlands
State/province [142] 0 0
Utrecht
Country [143] 0 0
Netherlands
State/province [143] 0 0
Zutphen
Country [144] 0 0
New Zealand
State/province [144] 0 0
Christchurch
Country [145] 0 0
New Zealand
State/province [145] 0 0
Hamilton
Country [146] 0 0
New Zealand
State/province [146] 0 0
Tauranga
Country [147] 0 0
New Zealand
State/province [147] 0 0
Wellington
Country [148] 0 0
Peru
State/province [148] 0 0
Trujillo
Country [149] 0 0
Poland
State/province [149] 0 0
Debica
Country [150] 0 0
Poland
State/province [150] 0 0
Lancut
Country [151] 0 0
Poland
State/province [151] 0 0
Wroclaw
Country [152] 0 0
Russian Federation
State/province [152] 0 0
Chelyabinsk
Country [153] 0 0
Russian Federation
State/province [153] 0 0
Saint-Petersburg
Country [154] 0 0
Russian Federation
State/province [154] 0 0
St. Petersburg
Country [155] 0 0
Russian Federation
State/province [155] 0 0
Stavropol
Country [156] 0 0
Russian Federation
State/province [156] 0 0
Yaroslavl
Country [157] 0 0
Singapore
State/province [157] 0 0
Singapore
Country [158] 0 0
Slovakia
State/province [158] 0 0
Bratislava
Country [159] 0 0
Slovakia
State/province [159] 0 0
Malacky
Country [160] 0 0
Slovakia
State/province [160] 0 0
Michalovce
Country [161] 0 0
Slovakia
State/province [161] 0 0
Svidnik
Country [162] 0 0
South Africa
State/province [162] 0 0
Cape Town
Country [163] 0 0
South Africa
State/province [163] 0 0
Centurion
Country [164] 0 0
South Africa
State/province [164] 0 0
Durban
Country [165] 0 0
South Africa
State/province [165] 0 0
Krugersdorp
Country [166] 0 0
South Africa
State/province [166] 0 0
Pretoria
Country [167] 0 0
South Africa
State/province [167] 0 0
Thabazimbi
Country [168] 0 0
Spain
State/province [168] 0 0
Barcelona
Country [169] 0 0
Spain
State/province [169] 0 0
Donostia-San Sebastian
Country [170] 0 0
Spain
State/province [170] 0 0
Elche
Country [171] 0 0
Spain
State/province [171] 0 0
Getafe
Country [172] 0 0
Spain
State/province [172] 0 0
Granada
Country [173] 0 0
Spain
State/province [173] 0 0
L'Hospitalet de Llobregat
Country [174] 0 0
Spain
State/province [174] 0 0
Madrid
Country [175] 0 0
Spain
State/province [175] 0 0
Mataro
Country [176] 0 0
Spain
State/province [176] 0 0
Santiago de Compostela
Country [177] 0 0
Spain
State/province [177] 0 0
Terrassa
Country [178] 0 0
Spain
State/province [178] 0 0
Vigo
Country [179] 0 0
Sweden
State/province [179] 0 0
Malmö
Country [180] 0 0
Sweden
State/province [180] 0 0
Umeå
Country [181] 0 0
Sweden
State/province [181] 0 0
Uppsala
Country [182] 0 0
Taiwan
State/province [182] 0 0
Kaohsiung
Country [183] 0 0
Taiwan
State/province [183] 0 0
Taipei
Country [184] 0 0
Thailand
State/province [184] 0 0
Bangkok
Country [185] 0 0
Thailand
State/province [185] 0 0
Muang
Country [186] 0 0
Thailand
State/province [186] 0 0
Wattana
Country [187] 0 0
Turkey
State/province [187] 0 0
Ankara
Country [188] 0 0
Turkey
State/province [188] 0 0
Aydin
Country [189] 0 0
Turkey
State/province [189] 0 0
Diyarbakir
Country [190] 0 0
Turkey
State/province [190] 0 0
Kocaeli
Country [191] 0 0
Turkey
State/province [191] 0 0
Samanpazari, Altindag
Country [192] 0 0
Turkey
State/province [192] 0 0
Trabzon
Country [193] 0 0
Ukraine
State/province [193] 0 0
Kharkiv
Country [194] 0 0
Ukraine
State/province [194] 0 0
Kyiv
Country [195] 0 0
Ukraine
State/province [195] 0 0
Poltava
Country [196] 0 0
Ukraine
State/province [196] 0 0
Vinnytsia
Country [197] 0 0
Ukraine
State/province [197] 0 0
Zhytomyr
Country [198] 0 0
United Kingdom
State/province [198] 0 0
Aberdeen
Country [199] 0 0
United Kingdom
State/province [199] 0 0
Edinburgh
Country [200] 0 0
United Kingdom
State/province [200] 0 0
Leeds
Country [201] 0 0
United Kingdom
State/province [201] 0 0
Manchester
Country [202] 0 0
United Kingdom
State/province [202] 0 0
Taunton
Country [203] 0 0
Vietnam
State/province [203] 0 0
Hanoi
Country [204] 0 0
Vietnam
State/province [204] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
Trial website
https://clinicaltrials.gov/study/NCT03376321
Trial related presentations / publications
Young B, Tan TT, Leo YS. The place for remdesivir in COVID-19 treatment. Lancet Infect Dis. 2021 Jan;21(1):20-21. doi: 10.1016/S1473-3099(20)30911-7. Epub 2020 Nov 26. No abstract available.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03376321